Citadel Advisors’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Citadel Advisors’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-158	Closed	-$42K	–	9910
2019 Q2	$42K	Sell	158 -49	-24%	-$16.4K	﹤0.01%	8783
2019 Q1	$78K	Buy	207 +147	+245%	+$49.3K	﹤0.01%	8647
2018 Q4	$22K	Buy	60 +7	+13%	+$2.75K	﹤0.01%	8716
2018 Q3	$23K	Sell	53 -7	-12%	-$2.95K	﹤0.01%	8992
2018 Q2	$22K	Buy	+60	New	+$28.3K	﹤0.01%	8633
2015 Q3	–	Sell	-1	Closed	-$3K	–	9321
2015 Q2	$3K	Buy	+1	New	+$3.14K	﹤0.01%	8602
2014 Q3	–	Sell	-3	Closed	-$11K	–	8490
2014 Q2	$11K	Buy	3 +2	+200%	+$7.53K	﹤0.01%	7553
2014 Q1	$3K	Sell	1 -1	-50%	-$4.46K	﹤0.01%	7706
2013 Q4	$7K	Sell	2 -5	-71%	-$18.9K	﹤0.01%	6783
2013 Q3	$30K	Hold	7	–	–	﹤0.01%	6043
2013 Q2	$72K	Buy	+7	New	+$77.5K	﹤0.01%	5448

Other funds holding FRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citadel Advisors's FRTX Position: Q2 2022 in Review

Citadel Advisors sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2022, closing a stake of 3,054 shares — an estimated $37K sold.

Citadel Advisors first reported a position in FRTX in Q2 2013 and held it in 20 quarters. The position peaked at $189K in Q3 2013. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2022.

Citadel Advisors reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Citadel Advisors sold 3,054 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $37K.
Citadel Advisors first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 20 quarters.
Citadel Advisors's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $189K in Q3 2013.
22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.